evidence review

NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence Peter Walter Barry; Kate Kelley; Toni Tan; Ilora Finlay In 2021, the National Institute for Health and Care Excellence produced an evidence-based guideline on the diagnosis and management of myalgic...

After an appeal by Janssen (the pharmaceutical company that manufactures esketamine) in July, NICE reviewed the evidence they submitted again in a technology appraisal guidance (TAG) and recommended against its use for treatment-resistant depression. The TAG committee’s discussion is an...

Glenton C, Lewin S, Downe S, et al. Cochrane Effective Practice and Organisation of Care (EPOC) Qualitative Evidence Syntheses, Differences From Reviews of Intervention Effectiveness and Implications for Guidance. International Journal of Qualitative Methods. January 2022...

" MEAction Response to CDC #MEAction has released a draft response to the CDC’s flawed systematic evidence review on ME/CFS treatments. Sign our form by August 15, 2021 to have your name added to #MEAction’s response before we formally submit it as a public comment on August 16." " CDC review...

The summary of the IOM report reads (p. 10, bolding mine): It is encouraging to note that progress already is being made in understanding the etiology, natural history, pathophysiology, and effective treatment of ME/CFS using a variety of physiological and molecular methods. Several large...

A thread announcing consultation on the draft document has been merged with this thread. Go to this post for the start of the merged thread. Consultation period 90 days from 17th May 2021. See this thread for commentary on the finalised evidence review: (CDC) Diagnosis and Treatment of...